RxDoctor Payments Data

Courtland Schoenhals, PA

Physician Assistant · Enid, OKNPI 1194326496

Payments from drug & device makers

$1,491in general payments, 2019–2025

Across 80 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$281
  • AbbVie$221
  • AstraZeneca$220
  • GSK$162
  • Exact Sciences$127
  • Myriad Women's Health, Inc.$79
  • plus $400 from 12 others

What the payments were for

  • Food & beverage$1,491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,491 in reported general payments places this provider in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$4,912
Medicare patients
70
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide130$157,523
TrulicityDulaglutide44$58,186
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$57,323
MounjaroTirzepatide45$55,127
JardianceEmpagliflozin47$49,239
Tresiba Flextouch U-200Insulin Degludec33$41,839
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$38,146
FarxigaDapagliflozin Propanediol47$32,610
RybelsusSemaglutide28$26,040
SynjardyEmpagliflozin/Metformin Hcl13$20,061
EliquisApixaban18$17,887
SymbicortBudesonide/Formoterol Fumarate57$16,624
LinzessLinaclotide12$15,058
Spiriva RespimatTiotropium Bromide24$12,227
MyrbetriqMirabegron18$9,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$71$183,563158 claims
Lilly USA, LLCTrulicity, Mounjaro$57$113,31489 claims
Boehringer IngelheimJardiance, Synjardy, Spiriva Respimat, Tradjenta$28$89,02396 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$220$87,380142 claims
GSKTrelegy Ellipta$162$57,32370 claims
PfizerEliquis$27$17,88718 claims
AbbVieLinzess$221$15,05812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →